title: Cefuroxime utilization evaluation: impact of physician education on prescribing patterns.
abstract: BACKGROUND
  Cefuroxime is a second-generation cephalosporin antibiotic used widely for the treatment of various infections.
  
  
  OBJECTIVE
  To assess the appropriateness of cefuroxime usage as well as the long-term impact of re-feeding the results to prescribing physicians.
  
  
  METHODS
  Drug utilization evaluation involved three data-collecting periods, each comprising 6 weeks, during which all patients receiving cefuroxime were evaluated. Results of phase I were distributed to all physicians in a newsletter and departmental lectures; phase II was announced and conducted 6 months later. An identical phase III was unannounced and conducted one year after phase II. The study included all patients receiving cefuroxime during the three phases. The main outcome measure was appropriateness of initiation, and continuation beyond 3 days, of empirical treatment. Appropriateness was determined according to a prepared list of indications based on the literature and the hospital's protocols.
  
  
  RESULTS
  Cefuroxime was initiated appropriately in 104 of 134 patients (78%) in phase I, in 85 of 100 (85%) in phase II, and in 93 of 100 (93%) in phase III (P < 0.001). Cefuroxime was continued appropriately after 3 days in 58/134 (43%), 57/100 (57%) and 70/100 (70%) respectively (P < 0.001). The total number of appropriate treatment days out of all treatment days increased from 516 of 635 (81%) in phase I, to 450 of 510 (88%) in phase II, to 485 of 509 (95%) in phase III (P < 0.001). The principal reason for cefuroxime usage was community-acquired respiratory tract infection.
  
  
  CONCLUSIONS
  Drug utilization evaluation may provide valuable data on the usage of a particular drug. This information, once re-fed to physicians, may improve utilization of the particular drug. This positive effect may be prolonged beyond the immediate period of observation.
authors.affiliation: Infectious Diseases Unit, Shaare Zedek Medical Center, Jerusalem, Israel. Yinnon@SZMC.org.il
authors.forename: A M
authors.initials: AM
authors.lastname: Yinnon
authors.forename: Y
authors.initials: Y
authors.lastname: Skorohod
authors.forename: Y
authors.initials: Y
authors.lastname: Schlesinger
authors.forename: A
authors.initials: A
authors.lastname: Greenberg
mesh_terms: D002444:Cefuroxime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004363:Drug Utilization; D004502:Education, Medical, Continuing; D019983:Guideline Adherence; D006801:Humans; D017410:Practice Guidelines as Topic; D012141:Respiratory Tract Infections / Q000188:drug therapy
chemical_list: D002511:Cephalosporins; D002444:Cefuroxime